PreludeDx: Chris Emery
PreludeDx has appointed Chris Emery as its VP of strategic marketing and business development, a newly created role to support the company in expanding market adoption of its ductal carcinoma in situ (DCIS) risk assessment test. Emery has more than 25 years of experience working with laboratory services, medical device, and biopharmaceutical companies. He joins PreludeDx from Halo Precision Diagnostics where he served as the chief business officer of molecular diagnostics. Prior to that he served in various leadership roles with Menarini, Abbott, Novartis, and LabCorp. He obtained his executive MBA from Pepperdine University and his BA in communications studies from University of California, San Diego.